

Encode SARS-COV-2 Antigen Rapid Test Device

is effective against the new coronavirus Omicron (B.1.1.529)

The coronavirus disease(COVID-19) continues, and SRAS-COV-2 continues to produce new mutant strains.In order to ensure quality of product, Zhuhai Encode Medical Engineering Co., Ltd. has paid close attention to the SARS-CoV-2 mutants reported by WHO and GISAID, and verified Variants of Concern in time.In the early stage, we have completed the verification of Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1) and Delta (B.1.617.2),using SARS-COV-2 Antigen Rapid Test Device produced by our company.Since the emergence of Omicron (B.1.1.529) ,we immediately proceeded to carry out relevant evaluations, using the corresponding recombinant N protein.The results showed that SARS-COV-2 Antigen Rapid Test Device produced by our company could efficiently detected Alpha(B.1.1.7),Beta(B.1.351),Gamma (P.1) ,Delta(B.1.617.2) and Omicron(B.1.1.529).

Zhuhai Encode Medical Engineering Co., Ltd

2021-12-8



银科医学的新冠病毒抗原检测试剂对新型冠状病毒 Omicron（B.1.1.529）依然有效

新冠疫情持续发展，新冠病毒不断产生新的突变。为保证产品质量，珠海市银科医学工程股份有限公司密切关注着 WHO、GISAID 等报告的 SARS-COV-2 突变株，及时对“密切关注突变体”进行验证。前期我们已经完成对“密切关注突变体”Alpha（B.1.1.7）、Beta（B.1.351）、Gamma（P1）以及 Delta（B.1.617.2）的验证，采用我公司生产的新型冠状病毒抗原检测试剂均可检出。Omicron(B.1.1.529)突变株出现后，我公司立即着手相关评估，利用相应的重组 N 蛋白对我公司生产的新型冠状病毒抗原检测试剂进行验证，本产品依然可以检出 Omicron（B.1.1.529）。

珠海市银科医学工程股份有限公司

2021-12-8

